FAP and cancer: A significant study employing a transgenic mouse model engineered to express the diphtheria toxin receptor under the FAP promoter demonstrated that depletion of FAP+ CAFs via diphtheria toxin enhanced the efficacy of anti-cancer vaccines (220).